CRISPR Therapeutics (CRSP) highlights strategic priorities and anticipated 2026 milestones; -Starting 2026 with a strong balance sheet with approximately USD 2bln in cash, cash equivalents, and marketable securities

• Continued global commercialization and adoption of CASGEVY, with ongoing quarterly updates.
• Global regulatory submissions for CASGEVY in patients ages 5 – 11 are expected to be initiated by Vertex in the first half of 2026.
• Updates from CTX310® are expected in the second half of 2026.
• Updates from the Lp(a) program are expected in 2026.
• Top-line Phase 2 clinical data from CTX611 in patients undergoing total knee arthroplasty (TKA) are expected in the second half of 2026.
• Updates across autoimmune disease and immuno-oncology for zugocabtagene geleucel (zugo-cel; formerly CTX112™) are expected in the second half of 2026.
• The Company expects to initiate a clinical trial for CTX460 in alpha-1 antitrypsin deficiency (AATD) in mid-2026.
• The Company expects to initiate a clinical trial for CTX340 in refractory hypertension in the first half of 2026.

CRISPR Therapeutics is positioning itself for a transformative 2026 with significant milestones and a robust balance sheet, suggesting strong operational health. The planned updates and regulatory submissions reflect a focused push towards global commercialization of their therapies, which could significantly impact investor sentiment in both the biotech sector and broader markets. This proactive stance will likely be crucial in navigating the competitive landscape and could influence trading volumes and price movements ahead of key data releases.